Belgium's Argenx Advances On More Positive Efgartigimod Data

Filing Imminent For Promising Myasthenia Gravis Therapy

Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.

Documents
Positive data keeps piling up for efgartigimod • Source: Shutterstock

With a US filing for efgartigimod imminent, Belgian biotech argenx N.V. has presented more positive data on the potential first-in-class product which has been touted as a future standard of care for the rare autoimmune disease myasthenia gravis.

Additional data from the previously reported Phase III ADAPT trial which enrolled patients who were either acetylcholine receptor-antibody (AChR-A) positive...

More from Rare Diseases

More from Scrip